World Health Organization Guidelines on Treatment of Hepatitis C Virus Infection: Best Practice Advice From the American College of Physicians

This advice from the US perspective, based on the WHO guidance, states that adults without cirrhosis should receive sofosbuvir–velpatasvir (S/V) for 12wks or glecaprevir–pibrentasvir (G/P) for 8wks. Those with compensated cirrhosis should receive S/V for 12wks or G/P for 12wks

Source:

Annals of Internal Medicine